Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700.

Article  CAS  PubMed  Google Scholar 

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022;40:1616–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13–24.

Article  CAS  PubMed  Google Scholar 

Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39:2294–303.

Article  CAS  PubMed  Google Scholar 

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Virgo KS, Rumble RB, Talcott J. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41:3652–6.

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021;205:14–21.

Article  PubMed  Google Scholar 

Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023;209:1082–90.

Article  PubMed  Google Scholar 

Mottet N, Cornford P, van den Berg RCN, Briers E, Eberli D, De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. 2023. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf.

Tagawa ST, Sandin R, Sah J, Mu Q, Freedland SJ. 679P Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study. Ann Oncol. 2020;31:S541–2.

Article  Google Scholar 

Freedland SJ, Sandin R, Sah J, Emir B, Mu Q, Ratiu A, et al. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. Cancer Med. 2021;10:8570–80.

Article  PubMed  PubMed Central  Google Scholar 

Ryan CJ, Ke X, Lafeuille M-H, Romdhani H, Kinkead F, Lefebvre P, et al. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. J Urol. 2021;206:1420–9.

Article  PubMed  PubMed Central  Google Scholar 

Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, et al. Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States. Cancers (Basel). 2021;13:4951.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, et al. Real-world use of androgen-deprivation therapy: Intensification among older canadian men with de novo metastatic prostate cancer. JNCI Cancer Spectr. 2021;5:pkab082.

Article  PubMed  PubMed Central  Google Scholar 

Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, et al. Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. J Clin Oncol. 2021;39(15_suppl):5072.

Article  Google Scholar 

George DJ, Agarwal N, Rider JR, Li B, Shirali R, Sandin R, et al. Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. J Clin Oncol. 2021;39(15_suppl):5074.

Article  Google Scholar 

Yip S, Niazi T, Hotte SJ, Lavallee L, Finelli A, Kapoor A, et al. Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study. J Clin Oncol. 2022;40(6_suppl):86.

Article  Google Scholar 

Freedland SJ, Klaassen ZWA, Agarwal N, Sandin R, Leith A, Ribbands A, et al. Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): A physician survey linked to patient chart reviews in the United States. J Clin Oncol. 2022;40(16_suppl):5065.

Article  Google Scholar 

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014;84:386–92.

Article  PubMed  Google Scholar 

Moses KA, Orom H, Brasel A, Gaddy J, Underwood W 3rd. Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urol Oncol. 2016;34:415.e7–12

Article  PubMed  Google Scholar 

Gerhard RS, Patil D, Liu Y, Ogan K, Alemozaffar M, Jani AB, et al. Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. Urol Oncol. 2017;35:250–6.

Article  PubMed  PubMed Central  Google Scholar 

Khan S, Hicks V, Rancilio D, Langston M, Richardson K, Drake BF. Predictors of Follow-Up Visits Post Radical Prostatectomy. Am J Mens Health. 2018;12:760–5.

Article  PubMed  PubMed Central  Google Scholar 

Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, Bolton A, Schwartz K, Schwartz AG, et al. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation. Cancer Med. 2019;8:3325–35.

Article  PubMed  PubMed Central  Google Scholar 

Caram MEV, Burns J, Kumbier K, Sparks JB, Tsao PA, Chapman CH, et al. Factors influencing treatment of veterans with advanced prostate cancer. Cancer. 2021;127:2311–8.

Article  CAS  PubMed  Google Scholar 

Mouzannar A, Atluri VS, Mason M, Prakash NS, Kwon D, Nahar B, et al. PD34-03 Racial disparity in the utilization of new therapies for advanced prostate cancer. J Urol. 2021;206(3_suppl):e583.

Article  Google Scholar 

Rude T, Walter D, Ciprut S, Kelly MD, Wang C, Fagerlin A, et al. Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. Cancer. 2021;127:3985–90.

Article  PubMed  Google Scholar 

Kelly SP, Rosenberg PS, Anderson WF, Andreotti G, Younes N, Cleary SD, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. 2017;71:195–201.

Article  PubMed  Google Scholar 

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017;123:2312–9.

Article  PubMed  Google Scholar 

Weiner AB, Matulewicz RS, Tosoian JJ, Feinglass JM, Schaeffer EM. The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013). Urol Oncol. 2018;36:91.e91–6.

Article  Google Scholar 

DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69:211–33.

Article  PubMed  Google Scholar 

Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, et al. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. Int J Urol. 2021;28:862–9.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

Article  PubMed  Google Scholar 

Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, et al. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Netw Open. 2022;5:e2144027.

Article  PubMed  PubMed Central  Google Scholar 

Elliott B, Zackery DL, Eaton VA, Jones RT, Abebe F, Ragin CC, et al. Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity. Carcinogenesis. 2018;39:546–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Dong Y, Sartor O, Flemington EK, Zhang K. SEER and Gene Expression Data Analysis Deciphers Racial Disparity Patterns in Prostate Cancer Mortality and the